Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...

State of Alaska Department of Revenue decreased its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 5.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned ...

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...

Others jostling for market share include Alkermes' Aristada (aripiprazole lauroxil), which is administered every six or eight weeks. The CRL is a setback to Teva as it tries to rebuild its ...